An observational study in Constipation, Incontinence and Hirschsprung Disease, Long-Segment, sponsored by Weibing Tang. Status unknown at 1 site in China. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2022-12-01.
Sponsored by Weibing Tang · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Constipation with a site in China — 35 open to participants now, 37 under way, 1 of them phase 3. Constipation · China.
Among the 109 studies in Constipation with a site in China, this one is the 13th largest by planned enrollment of the 16 observational ones that give a count, is one of 7 that started in 2022, is one of 16 observational ones, and was the 55th registered.
1,051 studies on the registry are indexed under Constipation; 163 are open to participants now.
Browse Constipation studies →35 of the 109 studies in Constipation with a site in China are open now. Recruiting first, the newest first:
Wecare Probiotics Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Wecare Probiotics Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Wecare Probiotics Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Tongji Hospital · Sites in China
Ages 18–75
Eli Lilly and Company · Sites in China, United States, Belgium and 5 more countries
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 3 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 23 · Phase 3 9 · Phase 4 3
First in 2004; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 120 across 126 observational studies indexed under Constipation.
Median enrollment 100 across the 93 interventional studies, 278 across the 16 observational. Of the 50 that completed or were terminated, 6 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 109 have an industry lead sponsor. The 10 most frequent:
Weibing Tang is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Weibing Tang has 2 studies filed under Constipation — fewer than ten, so there is no comparison to draw.
13 of the studies in Constipation with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07277907Phase 3Third Military Medical UniversityEfficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation | 2027-10-31 |
| NCT07507955Wecare Probiotics Co., Ltd.Probiotics for Constipation Relief in Adults | 2026-11-30 |
| NCT07765004Wecare Probiotics Co., Ltd.Probiotics Improve Constipation | 2026-12-15 |
| NCT07648394China-Japan Friendship HospitalResearch on the Efficacy and Mechanism of Shouhui Tongbian Capsules in Treating Postoperative Constipation of Benign Anal and Rectal Diseases Based on Gut Microbiota Analysis | 2026-12-31 |
| NCT07387952Peking Union Medical College HospitalThe Safety and Efficacy of Fecal Microbiota Transplantation Combined With Nutritional Intervention in the Treatment of Functional Constipation:a Pilot Study | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 109 studies in Constipation with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hirschsprung disease (HSCR) is characterized by the absence of ganglion cells (aganglionosis) in the distal bowel extending proximally for varying distances that results in persistent spasm in the affected bowel and functional intestinal obstruction. Patients can be classified as rectosigmoid HSCR when aganglionosis confined to the rectosigmoid and long-segment or total colonic HSCR when aganglionosis extends beyond the upper sigmoid. Aganglionosis of long-segment HSCR can extend to the descending colon, transverse colon, ascending colon, but not to the terminal ileum. To date, there is insufficient evidence to recommend a preferred or superior method for the surgical repair for long-segment HSCR. In general, a pull-through with standard of care for the intestine and mesentery, which avoids excessive resection of the colon and coloanal reconstruction, is performed for long-segment HSCR.There are reports that a significant percentage of long-segment HSCR patients continue to have difficulty with soiling and incontinence,however there were also reports long-segment HSCR patients have the same continece as rectosigmoid HSCR.The outcome of long-segment HSCR should be thoroughly evaluated. The present study was designed to evaluate the long-term outcomes of long-segment HSCR.
Hirschsprung disease (HSCR) is characterized by the absence of ganglion cells (aganglionosis) in the distal bowel extending proximally for varying distances that results in persistent spasm in the affected bowel and functional intestinal obstruction. Patients can be classified as rectosigmoid HSCR when aganglionosis confined to the rectosigmoid and long-segment or total colonic HSCR when aganglionosis extends beyond the upper sigmoid. Aganglionosis of long-segment HSCR can extend to the descending colon, transverse colon, ascending colon, but not to the terminal ileum. To date, there is insufficient evidence to recommend a preferred or superior method for the surgical repair for long-segment HSCR. In general, a pull-through with standard of care for the intestine and mesentery, which avoids excessive resection of the colon and coloanal reconstruction, is performed for long-segment HSCR.There are reports that a significant percentage of long-segment HSCR patients continue to have difficulty with soiling and incontinence,however there were also reports long-segment HSCR patients have the same continece as rectosigmoid HSCR.The outcome of long-segment HSCR should be thoroughly evaluated. The present study was designed to evaluate the long-term outcomes of long-segment HSCR.
The long-term outcome would be indicated by bowel function SCORE.
patients with with rectosigmoid and long-segment Hirschsprung disease after operation.
The follow-up age must more than 3 years old.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical diagnosis of Hirschsprung disease Must be performed with the operation of pull-through Must be followed up more than 3 years
Exclusion Criteria:
Clinical diagnosis of Down syndrome Clinical diagnosis of tolal colonic Hirschsprung disease Clinical diagnosis of degestive malformation except Hirschsprung disease
Aganglionosis of non-rectosigmoid HSCR can extend to the descending colon, transverse colon, ascending colon, but not to the terminal ileum
Other: questionnaire survey
Aganglionosis confined to the rectosigmoid
Other: questionnaire survey
questionnaire survey the long term outcomes of long-segment HSCR and compared with rectosigmoid HSCR
Bowel function score
Bowel function was evaluated by the BFS (20 points), which was approved by Rintala in 1995 ; patients with a score \> 18 were considered to have normal bowel habits.
Time frame: through study completion, an average of 5 year
Hirschspurng disease associated entrocolitis(HAEC)
The guidelines for the diagnosis and management of HAEC were defined by the American Pediatric Surgical Association in 2017
Time frame: through study completion, an average of 5 year
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2022 (actual). Primary completion is estimated for Aug 2023, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weibing Tang